[go: up one dir, main page]

WO1997033169A1 - Methode pour determiner l'affinite des proteines a l'egard des agents chimiques lors du criblage des bibliotheques combinatoires - Google Patents

Methode pour determiner l'affinite des proteines a l'egard des agents chimiques lors du criblage des bibliotheques combinatoires Download PDF

Info

Publication number
WO1997033169A1
WO1997033169A1 PCT/US1997/003625 US9703625W WO9733169A1 WO 1997033169 A1 WO1997033169 A1 WO 1997033169A1 US 9703625 W US9703625 W US 9703625W WO 9733169 A1 WO9733169 A1 WO 9733169A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
protein
affinity
gradient
target
Prior art date
Application number
PCT/US1997/003625
Other languages
English (en)
Other versions
WO1997033169A9 (fr
Inventor
Damien J. Dunnington
Dennis Shinji Yamashita
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP9531978A priority Critical patent/JP2000508624A/ja
Priority to EP97908953A priority patent/EP1025437A4/fr
Publication of WO1997033169A1 publication Critical patent/WO1997033169A1/fr
Publication of WO1997033169A9 publication Critical patent/WO1997033169A9/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/00513—Essentially linear supports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/00497—Features relating to the solid phase supports
    • B01J2219/00527—Sheets
    • B01J2219/00536—Sheets in the shape of disks
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof

Definitions

  • Such criteria may include one or more of the following: selectivity for one target versus a mutant form or closely related protein, binding affinity for the protein target, or binding to the active site of an enzyme versus allosteric or non-specific sites.
  • Current methods for evaluating compounds against these criteria require production of the compound in a soluble form and separate testing. For example to measure the binding affinity of a agonist or antagonist ligand for a receptor it is necessary to incubate multiple aliquots of the compound with the receptor over a range of compound concentration. This is both tedious and time consuming and requires the availability of relatively large amounts of compound.
  • a novel method for determining the affinity of a compound for a protein target during screens of combinatorial libraries on solid phase supports is described below.
  • This invention relates to an improved method of biological evaluation of combinatorial libraries using a method that permits direct measurement of bonding affinity of compounds, to a biological target.
  • a prefered aspect of the invention provides a method for determining the affinity of target proteins for chemical agents during screening of combinatorial libraries which comprises: presenting a target protein with a gradient of compound concentrations on a solid support; and measuring the amount of bound target at each concentration.
  • This invention also relates to compounds identified using the this method. Preferably the amount of bound target is measured by imaging the distribution of protein bound to the support.
  • This invention also relates to a support for solid-phase compound synthesis bearing a non-uniform distribution of chemical coupling sites and to compound libraries synthesized on this support.
  • Fig. 1 depicts a fabrication of polymer disks with a radial distribution of coupling densities by coaxial extrusion.
  • Sc is the equivalent local concentration of coupling sites.
  • Fig. 2 depicts a fabrication of rods carrying a linear gradient of coupling densities.
  • the principle of this method is to present the protein target with a range of spatially localized compound concentrations and measure the amount of bound target at each concentration.
  • this is achieved by varying the coupling density of the compound to the support to create a gradient of surface compound density. Binding of protein to the compound gradients is measured by using reagents that generate an optical readout corresponding to the bound protein and subsequent imaging the distribution of bound protein with compound density.
  • the key components of this invention are a solid support fabricated with a gradient of chemical coupling sites for compound attachment, a protein target of pharmaceutical interest, accessory reagents for generation of an optical signal and a quantitative imaging apparatus for measurement of the optical signal.
  • the solid phase support is critical for this method and is fabricated with a predictable gradient of chemical coupling sites. Gradients are constructed on disks, rods, ellipsoids, beads or other substrate geometries.
  • the preferred configurations are disks or rods (Figs. 1 , 2).
  • the number of chemical coupling sites on a given polymer is controlled by 'doping' of chemically selective linkers, photochemical activation/inactivation of sensitized coupling groups or controlled blocking of unwanted sites by chemical means, such as removing a reactive site from a Wang linker with an alkylating agent such as methyl iodide or removing a reactive site from a Merrifield linker with an alkoxide such as potassium methoxide or removing a reactive amine-containing linker with an acylating reagent such as benzoyl chloride.
  • Preferred substrates are Rapp Tentagel, a polyethylene glycol polymer, or Perseptive polystyrene-polyethylene glycol polymer because they are wettable with aqueous reagents. Disks carrying discontinuous gradients of coupling densities are fabricated by co-axial extrusion of cylinders of polymer carrying defined densities of coupling sites (Fig. 1.), followed by sectioning. Each layer of polymer is doped with a known concentration of linker prior to extrusion by addition of a specific concentration of linker to the polymer.
  • a 10 fold further dilution in linker sites use a 100: 1 ratio of unfunctionalized PEG to functionalized PEG, during the attachment step of the PEG units to the polystyrene particles.
  • a 1000: 1 ratio of unfunctionalized PEG to functionalized PEG during the attachment step of the PEG units to the polystyrene particles.
  • rods of polymer carrying photocleavable linkers can be extruded and during extrusion, the light level can be varied to inactivate the linkers in the desired spatial configuration (Fig. 2).
  • This approach allows fabrication of linear or exponential gradients.
  • Another method is to use photolithographic techniques to photoactivate or photoinactivate light-sensitive linkers in the desired gradient pattern on a photoreactive substrate, followed by die stamping to produce particles carrying the imprinted pattern.
  • the gradient may be linear, non-linear or discontinuous and the density range is chosen according to the needs of the screen. For example, if compounds with affinities for the protein target in the 10-100 nM range are desired, the gradient is fabricated to achieve an equivalent local concentration of compound ranging from 1 to 1000 nM.
  • the area occupied by the gradient is dependent on the limit of resolution of the imaging device. Typically, this limit is approximately 100 um for macro imaging with most CCD cameras, in which case, the gradient must occupy an area of at least 0.1 x 1 mm for a rectangular gradient, to allow resolution of 100 nM steps in equivalent compound concentration.
  • the use of high density CCD arrays and/or magnifying optics will permit higher resolution or smaller gradient areas at the expense of throughput, the latter being limited by the field area that can be imaged.
  • the equivalent local concentration of compound is estimated from the concentration of coupling sites within the polymer. For example, unmodified Rapp Tentagel contains -300 pmol coupling sites per 260 microM (swollen) bead.
  • linker This corresponds to a compound concentration within the polymer of -33 mM, assuming a monovalent linker is used and all the coupling sites are occupied.
  • the nature of the linker is chosen according to the desired chemistry of the subsequent combinatorial synthesis. Examples of well known linkers are those of Wang or Merrifield.
  • the result is a collection of particles, each with a gradient of local density of an individual compound.
  • the particles are screened against a protein target by addition of the particles to a solution of the protein target and by measurement of the optical signal associated with the protein.
  • the protein target may be soluble or membrane bound. It may be directly labelled with a substance capable of generating an optical signal.
  • the optical signal is fluorescence or luminescence. Fluorophores are attached to proteins by chemical means. A well known example is the use of fluorescein isothiocyanate which attaches fluorescein to amino groups in the protein.
  • the protein may be indirectly labelled by providing a fluorescently labelled antibody that recognises the protein itself, or a suitable tag incorporated within the sequence of the protein.
  • a fluorescently labelled antibody that recognises the protein itself, or a suitable tag incorporated within the sequence of the protein.
  • lipophilic fluorescent dyes are available from commercial sources, for example, 1,1'- dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine, available from Molecular Probes of Eugene, Or. Such dyes dissolve in membrane lipids and are used to label vesicles carrying receptors or other membrane-associated protein targets.
  • the particles Prior to the addition of the protein target, the particles may be treated with a high concentration of a blocking reagent to occupy non-specific protein binding sites.
  • blocking reagents examples include 1 % bovine serum albumin or casein.
  • the particle suspension is incubated to attain binding equilibrium. The incubation conditions will vary for each protein target, but in general, 2 hours at 37 degrees Celsius will suffice for most targets. The optimum protein concentration will depend on the sensitivity of the optical detection device and the binding affinity and number of active compounds in the library and may be determined empirically.
  • the particles are washed with a suitable buffer, for example, 10 mM HEPES pH 7.6, 0.15 mM sodium chloride, 0.1% NP-40.
  • a suitable buffer for example, 10 mM HEPES pH 7.6, 0.15 mM sodium chloride, 0.1% NP-40.
  • the particles are then spread onto a filter paper and imaged.
  • the optical signal may be detected by using a CCD camera, such as the Tundra instrument from Imaging Research Inc., St Catherine's, Ontario, Canada. Positive particles are selected by measuring the decrease of optical signal along the axis of the gradient. Compounds that bind the protein with high affinity will generate a signal at low compound densities, therefore the signal will extend into the regions of the gradient with low densities of such compounds.
  • compounds are ranked in order of binding affinity.
  • the compounds are identified. This may be done by cleaving the compound from each particle and subjecting it to analysis by mass spectrometry. Alternatively, the compounds may be tagged with specific chemical markers during synthesis, such that the nature of the compound is encoded by the tag. Methods for such tagging are well known to those skilled in the art.
  • An example of mass spectrometric compound identification is : A mass spectrometric solution to the address problem of combinatorial libraries, Brummel-CL; Lee-IN; Zhou-Y; Benkovic-SJ; Winograd-N, Science. 1994 264 (5157): 399-402.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Invention d'une méthode permettant de déterminer l'affinité des cibles protéiniques à l'égard des agents chimiques lors du criblage des bibliothèques combinatoires. Les bibliothèques sont synthétisées sur un support solide avec un gradient de sites de couplage afin d'exposer la cible à une gamme de concentrations de produits composés. La distribution de la protéine liée aux produits immobilisés est mesurée à l'aide de l'analyse quantitative de l'image. On classe les produits composés en fonction de leur affinité de liaison en comparant leur capacité de se lier par rapport au gradient.
PCT/US1997/003625 1996-03-08 1997-03-07 Methode pour determiner l'affinite des proteines a l'egard des agents chimiques lors du criblage des bibliotheques combinatoires WO1997033169A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP9531978A JP2000508624A (ja) 1996-03-08 1997-03-07 コンビナトリアルライブラリーのスクリーニングの間にタンパク質の化学物質に対する親和性を測定する方法
EP97908953A EP1025437A4 (fr) 1996-03-08 1997-03-07 Methode pour determiner l'affinite des proteines a l'egard des agents chimiques lors du criblage des bibliotheques combinatoires

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1313696P 1996-03-08 1996-03-08
US60/013,136 1996-03-08

Publications (2)

Publication Number Publication Date
WO1997033169A1 true WO1997033169A1 (fr) 1997-09-12
WO1997033169A9 WO1997033169A9 (fr) 1997-11-13

Family

ID=21758497

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/003625 WO1997033169A1 (fr) 1996-03-08 1997-03-07 Methode pour determiner l'affinite des proteines a l'egard des agents chimiques lors du criblage des bibliotheques combinatoires

Country Status (3)

Country Link
EP (1) EP1025437A4 (fr)
JP (1) JP2000508624A (fr)
WO (1) WO1997033169A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002084285A3 (fr) * 2001-04-18 2003-08-07 Ulrich J Krull Plate-forme d'information a resolution par gradient
EP1502102A4 (fr) * 2002-03-11 2005-11-09 Hk Pharmaceuticals Inc Composes et procedes pour analyser le proteome
GB2436976A (en) * 2006-04-05 2007-10-10 Agilent Technologies Inc Arrays and design thereof where probe abundance is varied in predetermined manner
US7291456B2 (en) 2002-01-24 2007-11-06 The Regents Of The University Of California Method for determining differences in molecular interactions and for screening a combinatorial library
US9034798B2 (en) 2003-01-16 2015-05-19 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545568A (en) * 1992-09-14 1996-08-13 The Regents Of The University Of California Solid phase and combinatorial synthesis of compounds on a solid support
EP0742438A2 (fr) * 1995-05-10 1996-11-13 Bayer Corporation Triage de librairie peptidiques combinatoires pour sélection de ligand peptidique utile à la purification d'affinité des protéines cibles
US5591646A (en) * 1992-09-02 1997-01-07 Arris Pharmaceutical Method and apparatus for peptide synthesis and screening

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5591646A (en) * 1992-09-02 1997-01-07 Arris Pharmaceutical Method and apparatus for peptide synthesis and screening
US5545568A (en) * 1992-09-14 1996-08-13 The Regents Of The University Of California Solid phase and combinatorial synthesis of compounds on a solid support
EP0742438A2 (fr) * 1995-05-10 1996-11-13 Bayer Corporation Triage de librairie peptidiques combinatoires pour sélection de ligand peptidique utile à la purification d'affinité des protéines cibles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1025437A4 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002084285A3 (fr) * 2001-04-18 2003-08-07 Ulrich J Krull Plate-forme d'information a resolution par gradient
US7183050B2 (en) 2001-04-18 2007-02-27 Krull Ulrich J Gradient resolved information platform
US7291456B2 (en) 2002-01-24 2007-11-06 The Regents Of The University Of California Method for determining differences in molecular interactions and for screening a combinatorial library
EP1502102A4 (fr) * 2002-03-11 2005-11-09 Hk Pharmaceuticals Inc Composes et procedes pour analyser le proteome
US7635564B2 (en) 2002-10-25 2009-12-22 Agilent Technologies, Inc. Biopolymeric arrays having replicate elements
US8093186B2 (en) 2002-10-25 2012-01-10 Agilent Technologies, Inc. Biopolymeric arrays having replicate elements
US9034798B2 (en) 2003-01-16 2015-05-19 Caprotec Bioanalytics Gmbh Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
GB2436976A (en) * 2006-04-05 2007-10-10 Agilent Technologies Inc Arrays and design thereof where probe abundance is varied in predetermined manner

Also Published As

Publication number Publication date
EP1025437A4 (fr) 2002-10-23
JP2000508624A (ja) 2000-07-11
EP1025437A1 (fr) 2000-08-09

Similar Documents

Publication Publication Date Title
CA2310684C (fr) Criblage a haut rendement en format continu
EP1002233B1 (fr) Technique a haut rendement
US20010012537A1 (en) Dry deposition of materials for microarrays using matrix displacement
Silzel et al. Mass-sensing, multianalyte microarray immunoassay with imaging detection
US6846635B1 (en) Microarrays and their manufacture
JP4997222B2 (ja) 多機能かつ構成可能なアッセイ
US20020015952A1 (en) Microarrays and their manufacture by slicing
US20030044855A1 (en) Microarrays and their manufacture by slicing
CA2114627A1 (fr) Trousse d'analyse quantitative en phase liquide d'oligonucleotides et methode d'utilisation
US7371584B2 (en) Multi-functional and configurable assay
US20040072274A1 (en) System and method for visualization and digital analysis of protein and other macromolecule microarrays
Martens et al. A generic particle-based nonradioactive homogeneous multiplex method for high-throughput screening using microvolume fluorimetry
JP3868267B2 (ja) マルチカラム・アフィニティー検出システム
WO1997033169A1 (fr) Methode pour determiner l'affinite des proteines a l'egard des agents chimiques lors du criblage des bibliotheques combinatoires
WO1997033169A9 (fr) Methode pour determiner l'affinite des proteines a l'egard des agents chimiques lors du criblage des bibliotheques combinatoires
WO2002010761A1 (fr) Microreseaux et leur fabrication par tranchage
Hoff et al. Lipoconjugates for the noncovalent generation of microarrays in biochemical and cellular assays
JP2002286717A (ja) 無蛍光担体およびこれを固相に用いた測定用セル、ならびに無蛍光担体を利用する濃度測定方法
US20050124017A1 (en) Quantitative alkaline-phosphatase precipitation reagent and methods for visualization of protein microarrays
US20070172905A1 (en) Method for screening process conditions of a chemical coupling reaction and kits therefor
JP2006501455A (ja) 分析対象物質の検出方法
CA2405815A1 (fr) Procede de detection et/ou de quantification de premieres molecules
Hardiman Protein Microarray Platform
JP2008233010A (ja) マイクロチャンバアレイを用いた蛍光偏光解消法による標的物質測定方法
HK1032996B (en) Continuous format high throughput screening using planar matrices

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGE 2,DESCRIPTION,AND PAGE 1/2,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;AFTER RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE INTERNATIONAL SEARCHING AUTHORITY

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 1997908953

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997908953

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1997908953

Country of ref document: EP